57 related articles for article (PubMed ID: 21567323)
1. Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens.
Zhao J; Cochrane CS; Najeeb J; Gooden D; Sciandra C; Fan P; Lemaitre N; Newns K; Nicholas RA; Guan Z; Thaden JT; Fowler VG; Spasojevic I; Sebbane F; Toone EJ; Duncan C; Gammans R; Zhou P
Sci Transl Med; 2023 Aug; 15(708):eadf5668. PubMed ID: 37556556
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, structure, and antibiotic activity of aryl-substituted LpxC inhibitors.
Liang X; Lee CJ; Zhao J; Toone EJ; Zhou P
J Med Chem; 2013 Sep; 56(17):6954-6966. PubMed ID: 23914798
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review of recent developments in the gram-negative bacterial UDP-2,3-diacylglucosamine hydrolase (LpxH) enzyme.
Karthikeyan D; Kumar S; Jayaprakash NS
Int J Biol Macromol; 2024 May; 267(Pt 2):131327. PubMed ID: 38574903
[TBL] [Abstract][Full Text] [Related]
4. Lipopolysaccharide lipid A: A promising molecule for new immunity-based therapies and antibiotics.
Garcia-Vello P; Di Lorenzo F; Zucchetta D; Zamyatina A; De Castro C; Molinaro A
Pharmacol Ther; 2022 Feb; 230():107970. PubMed ID: 34454000
[TBL] [Abstract][Full Text] [Related]
5. Microbial Primer: Lipopolysaccharide - a remarkable component of the Gram-negative bacterial surface.
VanOtterloo LM; Trent MS
Microbiology (Reading); 2024 Mar; 170(3):. PubMed ID: 38450586
[TBL] [Abstract][Full Text] [Related]
6. Biosynthesis, transport, and modification of lipid A.
Trent MS
Biochem Cell Biol; 2004 Feb; 82(1):71-86. PubMed ID: 15052329
[TBL] [Abstract][Full Text] [Related]
7. A method to assay inhibitors of lipopolysaccharide synthesis.
Hernick M; Fierke CA
Methods Mol Med; 2008; 142():143-54. PubMed ID: 18437312
[TBL] [Abstract][Full Text] [Related]
8. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
Cuny GD
Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of potent Gram-negative specific LpxC inhibitors.
Mansoor UF; Vitharana D; Reddy PA; Daubaras DL; McNicholas P; Orth P; Black T; Siddiqui MA
Bioorg Med Chem Lett; 2011 Feb; 21(4):1155-61. PubMed ID: 21273067
[TBL] [Abstract][Full Text] [Related]
10. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.
Tomaras AP; McPherson CJ; Kuhn M; Carifa A; Mullins L; George D; Desbonnet C; Eidem TM; Montgomery JI; Brown MF; Reilly U; Miller AA; O'Donnell JP
mBio; 2014 Sep; 5(5):e01551-14. PubMed ID: 25271285
[TBL] [Abstract][Full Text] [Related]
11. Fluorescence-based methods to assay inhibitors of lipopolysaccharide synthesis.
Hernick M
Methods Mol Biol; 2011; 739():123-33. PubMed ID: 21567323
[TBL] [Abstract][Full Text] [Related]
12. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
Liu F; Ma S
Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
